Literature DB >> 23901848

Acute antibody-mediated rejection in pediatric kidney transplants: a single center experience.

Katherine Twombley1, Lonnie Thach, Annelise Ribeiro, Catherine Joseph, Mouin Seikaly.   

Abstract

aAMR is a potentially devastating complication of kidney transplantation. The incidence of aAMR in children, while thought to be rare, is not well defined, and there is a paucity of data on treatment regimens in children. We retrospectively reviewed the outcomes of our pediatric patients that were treated for aAMR between 2007 and 2009. Three adolescent Hispanic males were found to have aAMR. All three received deceased donor transplants, and all three verbalized non-adherence. Treatment consisted of rituximab, solumedrol, PE, and IVIgG in one patient, and PE, IVIgG, and bortezomib in two patients. The only side effect of therapy noted was mild hypotension with rituximab that resolved after decreasing the infusion rate. There were no reported infections two yr after treatment, and all of the viral monitoring in these patients remained negative.
© 2013 John Wiley & Sons A/S.

Entities:  

Keywords:  adolescents; anti-HLA antibody; antibodies; antibody mediated rejection; outcome; pediatric kidney transplant

Mesh:

Substances:

Year:  2013        PMID: 23901848     DOI: 10.1111/petr.12129

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  7 in total

Review 1.  Antibody-mediated rejection in pediatric kidney transplantation: pathophysiology, diagnosis, and management.

Authors:  Yolanda W Ng; Manpreet Singh; Minnie M Sarwal
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

2.  Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients.

Authors:  Meghan Pearl; Patricia L Weng; Lucia Chen; Aditi Dokras; Helen Pizzo; Jonathan Garrison; Carrie Butler; Jennifer Zhang; Elaine F Reed; Irene K Kim; Jua Choi; Mark Haas; Xiaohai Zhang; Ashley Vo; Eileen Tsai Chambers; Robert Ettenger; Stanley Jordan; Dechu Puliyanda
Journal:  Clin Transplant       Date:  2022-06-12       Impact factor: 3.456

3.  Role of alloimmunity and autoimmunity in allograft rejection.

Authors:  Babak Banan; Zhongping Xu; Muthukumar Gunasekaran; T Mohanakumar
Journal:  Clin Transpl       Date:  2013

4.  Management of sensitized pediatric patients prior to renal transplantation.

Authors:  Kwanchai Pirojsakul; Dev Desai; Chantale Lacelle; Mouin G Seikaly
Journal:  Pediatr Nephrol       Date:  2016-01-22       Impact factor: 3.714

5.  Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection.

Authors:  Meghan H Pearl; Anjali B Nayak; Robert B Ettenger; Dechu Puliyanda; Miguel Fernando Palma Diaz; Qiuheng Zhang; Elaine F Reed; Eileen W Tsai
Journal:  Pediatr Nephrol       Date:  2016-04-05       Impact factor: 3.714

6.  Comparing Plasmapheresis plus IVIg with Plasmapheresis plus IVIg plus Rituximab on the Management of Suspicious Antibody-Mediated Acute Rejection in Kidney Transplant Recipients.

Authors:  F Ahmadi; S Dashti-Khavidaki; M R Khatami; M Gatmiri; F Ahmadi; M Mahdavi-Mazdeh; M T Najafi; Z Foroozanfar; A Mahdizadeh; S Derafshi
Journal:  Int J Organ Transplant Med       Date:  2019

Review 7.  Antibody-mediated rejection after kidney transplantation in children; therapy challenges and future potential treatments.

Authors:  Massimiliano Bertacchi; Paloma Parvex; Jean Villard
Journal:  Clin Transplant       Date:  2022-02-16       Impact factor: 3.456

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.